ViewRay, Inc. (VRAY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ViewRay, Inc. (VRAY) Healthcare & Pipeline Overview

ViewRay, Inc. designs, manufactures, and markets MRI-guided radiation therapy systems, offering a unique approach to cancer treatment. Their MRIdian system differentiates them within the medical device sector, focusing on enhanced precision and reduced toxicity in radiation therapy, serving university hospitals and cancer centers globally.

What Is the Investment Thesis for VRAY?

ViewRay, Inc. presents a compelling investment case centered on its innovative MRIdian MRI-guided radiation therapy system. The system's ability to visualize and adapt treatment in real-time offers a significant advantage over conventional radiation therapy, potentially leading to improved clinical outcomes and reduced side effects. Key value drivers include the increasing adoption of MRIdian systems by leading cancer centers, expansion into new geographic markets, and the development of new clinical applications for the technology. The company's gross margin of 9.8% indicates potential for improvement as the installed base grows and operational efficiencies are realized. Upcoming catalysts include new clinical data publications supporting the efficacy of MRIdian and regulatory approvals in key international markets. Potential risks include competition from established radiation therapy vendors and the capital-intensive nature of the medical device industry.

Based on FMP financials and quantitative analysis

VRAY Key Highlights

ViewRay, Inc. specializes in MRI-guided radiation therapy systems, offering a unique approach to cancer treatment.

• The company's MRIdian system integrates MRI technology with radiation therapy for real-time imaging and adaptive treatment planning.
• ViewRay serves university research hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers.
• The company's gross margin is 9.8%.
• ViewRay has a beta of 0.70, indicating lower volatility compared to the overall market.

Who Are VRAY's Competitors?

VRAY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VRAY's Key Strengths?

Innovative MRI-guided radiation therapy technology.

• Potential for improved clinical outcomes and reduced side effects.
• Established presence in leading cancer centers.
• Strong intellectual property protection.

What Are VRAY's Weaknesses?

Limited market share compared to established competitors.

• High system cost may limit adoption.
• Negative profit margin.
• Dependence on a single product line.

What Could Drive VRAY Stock Higher?

Publication of new clinical data supporting the efficacy of MRIdian.

• Regulatory approvals in key international markets.
• Expansion of the installed base of MRIdian systems.
• Development of new clinical applications for MRI-guided radiation therapy.

What Are the Key Risks for VRAY?

Financial-distress signal — its Altman Z-Score of -6.12 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-85.2%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
• Competition from established radiation therapy vendors.
• Technological advancements by competitors.
• Changes in healthcare reimbursement policies.
• Regulatory hurdles and delays.
• The company's negative profit margin poses a financial risk.

What Are the Growth Opportunities for VRAY?

• Expansion into Emerging Markets: ViewRay has the opportunity to expand its presence in emerging markets, where the demand for advanced cancer treatment technologies is growing rapidly. These markets often have less established competition and a greater need for innovative solutions like MRIdian. Successful entry into these markets could significantly increase ViewRay's installed base and revenue. The timeline for this expansion is ongoing, with a focus on regions with favorable regulatory environments and healthcare infrastructure development.
• Development of New Clinical Applications: ViewRay can drive growth by developing new clinical applications for its MRIdian system. This includes exploring the use of MRI-guided radiation therapy for treating different types of cancer and for addressing other medical conditions. Expanding the clinical utility of MRIdian would broaden its market appeal and increase its value proposition to healthcare providers. This is an ongoing process with potential for new applications emerging over the next 3-5 years.
• Strategic Partnerships and Collaborations: ViewRay can leverage strategic partnerships and collaborations to accelerate its growth. This includes partnering with leading cancer centers, research institutions, and technology companies to advance the development and adoption of MRIdian. Collaborations can provide access to new markets, technologies, and expertise, enhancing ViewRay's competitive position. These partnerships are ongoing and can lead to significant advancements in the field.
• Increased Adoption in Community Hospitals: While ViewRay currently serves university and research hospitals, there is a significant opportunity to increase adoption of MRIdian in community hospitals. These hospitals represent a large and underserved market for advanced radiation therapy technologies. By demonstrating the clinical and economic benefits of MRIdian, ViewRay can expand its reach and impact on cancer care within the community setting. This growth opportunity can be realized over the next 2-4 years.
• Enhancements in Artificial Intelligence (AI) and Machine Learning (ML): ViewRay can integrate AI and ML technologies into its MRIdian system to further enhance its capabilities. This includes using AI to automate treatment planning, optimize radiation delivery, and improve image quality. These enhancements can improve the efficiency and effectiveness of MRIdian, making it an even more valuable tool for cancer treatment. The integration of AI and ML is an ongoing process, with new advancements expected in the coming years.

What Are VRAY's Competitive Advantages?

• Proprietary MRI-guided radiation therapy technology.
• Strong intellectual property protection.
• Established relationships with leading cancer centers.
• High switching costs for customers due to system complexity and training requirements.

What Does VRAY Do?

ViewRay, Inc., founded in 2004 and headquartered in Oakwood, Ohio, is a medical device company focused on advancing cancer treatment through MRI-guided radiation therapy. The company's core product, MRIdian, integrates MRI technology with radiation therapy to provide real-time imaging during treatment. This allows clinicians to visualize the tumor and surrounding healthy tissue, adapt the treatment plan in real-time, and deliver radiation with greater precision. MRIdian addresses key challenges in radiation therapy, such as beam distortion and skin toxicity, aiming to improve treatment outcomes and reduce side effects for cancer patients. ViewRay serves a diverse customer base, including university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers across the United States, France, Taiwan, the United Kingdom, and other international markets. The company markets its MRIdian system through a direct sales force and distribution network, emphasizing the clinical benefits and technological advantages of its MRI-guided radiation therapy platform.

What Products and Services Does VRAY Offer?

• Designs and manufactures MRI-guided radiation therapy systems.
• Markets MRIdian, an MRI-guided radiation therapy system.
• Provides solutions for precise cancer treatment.
• Offers real-time imaging during radiation therapy.
• Addresses beam distortion and skin toxicity concerns.
• Serves university hospitals and cancer centers.
• Utilizes a direct sales force and distribution network.

How Does VRAY Make Money?

• Sells MRIdian MRI-guided radiation therapy systems.
• Provides service and maintenance contracts for installed systems.
• Generates revenue through system upgrades and software enhancements.

What Industry Does VRAY Operate In?

ViewRay operates within the medical device industry, specifically in the radiation therapy equipment market. This market is characterized by technological innovation, stringent regulatory requirements, and a competitive landscape dominated by established players. The increasing prevalence of cancer and the growing demand for more precise and effective treatment options are driving growth in the radiation therapy market. ViewRay's MRIdian system differentiates itself by integrating MRI guidance, offering a unique value proposition compared to traditional radiation therapy systems. The company competes with larger medical device companies that offer a range of radiation therapy solutions.

Who Are VRAY's Key Customers?

• University research and teaching hospitals
• Community hospitals
• Private practices
• Government institutions
• Freestanding cancer centers

ViewRay, Inc. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 0.6% above estimates on average.

ViewRay, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -6.12 places it in the distress zone, a signal of elevated financial risk.

Return on equity for ViewRay, Inc. stands at -85.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.5%, showing how much profit it generates from its asset base. A current ratio of 2.36 indicates the company holds enough short-term assets to cover its near-term obligations.

ViewRay, Inc. (VRAY) Valuation Context

Valued at $4.56M, VRAY is classified as a micro-cap stock. Relative to its peer group, VRAY's quantitative score of 56/100 is roughly in line with the peer average of 60/100.

Company Profile

ViewRay, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Oakwood, US. The company is led by CEO Paul Ziegler Jr.,. VRAY has traded publicly since 2015.

VRAY Financials

VRAY Latest News

No recent news available for VRAY.

VRAY Analyst Consensus

VRAY MoonshotScore

VRAY Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources